327 related articles for article (PubMed ID: 31674023)
21. Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer.
Xu W; Siddiqui IA; Nihal M; Pilla S; Rosenthal K; Mukhtar H; Gong S
Biomaterials; 2013 Jul; 34(21):5244-53. PubMed ID: 23582862
[TBL] [Abstract][Full Text] [Related]
22. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.
Dhar S; Gu FX; Langer R; Farokhzad OC; Lippard SJ
Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17356-61. PubMed ID: 18978032
[TBL] [Abstract][Full Text] [Related]
23. Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate.
Liu T; Nedrow-Byers JR; Hopkins MR; Wu LY; Lee J; Reilly PT; Berkman CE
Bioorg Med Chem Lett; 2012 Jun; 22(12):3931-4. PubMed ID: 22607680
[TBL] [Abstract][Full Text] [Related]
24. PSMA-mediated endosome escape-accelerating polymeric micelles for targeted therapy of prostate cancer and the real time tracing of their intracellular trafficking.
Gao Y; Li Y; Li Y; Yuan L; Zhou Y; Li J; Zhao L; Zhang C; Li X; Liu Y
Nanoscale; 2015 Jan; 7(2):597-612. PubMed ID: 25419788
[TBL] [Abstract][Full Text] [Related]
25. Characterization of rhodamine loaded PEG-g-PLA nanoparticles (NPs): effect of poly(ethylene glycol) grafting density.
Essa S; Rabanel JM; Hildgen P
Int J Pharm; 2011 Jun; 411(1-2):178-87. PubMed ID: 21458551
[TBL] [Abstract][Full Text] [Related]
26. Preparation, characterization, and in vitro evaluation of docetaxel-loaded poly(lactic acid)-poly(ethylene glycol) nanoparticles for parenteral drug delivery.
Liu D; Wang L; Liu Z; Zhang C; Zhang N
J Biomed Nanotechnol; 2010 Dec; 6(6):675-82. PubMed ID: 21361132
[TBL] [Abstract][Full Text] [Related]
27. Formulation and dosage of therapeutic nanosuspension for active targeting of docetaxel (WO 2014210485A1).
Pooja D; Kulhari H; Adams DJ; Sistla R
Expert Opin Ther Pat; 2016 Jul; 26(7):745-9. PubMed ID: 27088623
[TBL] [Abstract][Full Text] [Related]
28. PSMA Antibody-Conjugated Pentablock Copolymer Nanomicellar Formulation for Targeted Delivery to Prostate Cancer.
Owiti AO; Pal D; Mitra A
AAPS PharmSciTech; 2018 Nov; 19(8):3534-3549. PubMed ID: 30151731
[TBL] [Abstract][Full Text] [Related]
29. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
[No Abstract] [Full Text] [Related]
30. Targeted nanoparticles encapsulating (-)-epigallocatechin-3-gallate for prostate cancer prevention and therapy.
Sanna V; Singh CK; Jashari R; Adhami VM; Chamcheu JC; Rady I; Sechi M; Mukhtar H; Siddiqui IA
Sci Rep; 2017 Feb; 7():41573. PubMed ID: 28145499
[TBL] [Abstract][Full Text] [Related]
31. An effective strategy for development of docetaxel encapsulated gold nanoformulations for treatment of prostate cancer.
Thambiraj S; Vijayalakshmi R; Ravi Shankaran D
Sci Rep; 2021 Feb; 11(1):2808. PubMed ID: 33531521
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells.
Luo Y; Ling Y; Guo W; Pang J; Liu W; Fang Y; Wen X; Wei K; Gao X
J Control Release; 2010 Oct; 147(2):278-88. PubMed ID: 20655966
[TBL] [Abstract][Full Text] [Related]
33. PSMA-targeted stably linked "dendrimer-glutamate urea-methotrexate" as a prostate cancer therapeutic.
Huang B; Otis J; Joice M; Kotlyar A; Thomas TP
Biomacromolecules; 2014 Mar; 15(3):915-23. PubMed ID: 24392665
[TBL] [Abstract][Full Text] [Related]
34. Prostate Cancer Therapy Using Docetaxel and Formononetin Combination: Hyaluronic Acid and Epidermal Growth Factor Receptor Targeted Peptide Dual Ligands Modified Binary Nanoparticles to Facilitate the in vivo Anti-Tumor Activity.
Dong Z; Wang Y; Guo J; Tian C; Pan W; Wang H; Yan J
Drug Des Devel Ther; 2022; 16():2683-2693. PubMed ID: 35983428
[TBL] [Abstract][Full Text] [Related]
35. PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells.
Xu S; Cui F; Huang D; Zhang D; Zhu A; Sun X; Cao Y; Ding S; Wang Y; Gao E; Zhang F
Int J Nanomedicine; 2019; 14():17-32. PubMed ID: 30587982
[TBL] [Abstract][Full Text] [Related]
36. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA).
Chandran SS; Banerjee SR; Mease RC; Pomper MG; Denmeade SR
Cancer Biol Ther; 2008 Jun; 7(6):974-82. PubMed ID: 18698158
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs.
Kularatne SA; Venkatesh C; Santhapuram HK; Wang K; Vaitilingam B; Henne WA; Low PS
J Med Chem; 2010 Nov; 53(21):7767-77. PubMed ID: 20936874
[TBL] [Abstract][Full Text] [Related]
38. PSMA ligand conjugated PCL-PEG polymeric micelles targeted to prostate cancer cells.
Jin J; Sui B; Gou J; Liu J; Tang X; Xu H; Zhang Y; Jin X
PLoS One; 2014; 9(11):e112200. PubMed ID: 25386942
[TBL] [Abstract][Full Text] [Related]
39. PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice.
Langut Y; Talhami A; Mamidi S; Shir A; Zigler M; Joubran S; Sagalov A; Flashner-Abramson E; Edinger N; Klein S; Levitzki A
Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13655-13660. PubMed ID: 29229829
[TBL] [Abstract][Full Text] [Related]
40. PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer.
Flores O; Santra S; Kaittanis C; Bassiouni R; Khaled AS; Khaled AR; Grimm J; Perez JM
Theranostics; 2017; 7(9):2477-2494. PubMed ID: 28744329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]